Company Overview and News

 
Watts Water CFO Todd Trapp to leave the company

2018-03-30 marketwatch
We suggest investors to hold Watts Water Technologies (WTS) stock in their portfolio as it is poised to generate superior returns.
Upvote Downvote

16
5 Big Biotech Stocks to Buy Under $10

2018-03-20 investorplace
For investors, biotech stocks remain one of the most dynamic sectors out there. On one hand, you have some of the largest pharmaceutical firms on the planet with multi-billion-dollar blockbuster drugs filling their coffers. On the other, you have the more stereotypical “lotto ticket” biotech stocks of clinical or early production stage firms. These are the firms that live and die by the FDA’s decisions and their cash balances.
Upvote Downvote

2
Proteostasis Therapeutics (PTI) Looks Good: Stock Adds 8% in Session

2018-03-16 zacks
Proteostasis Therapeutics, Inc. (PTI - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 127.6% in the past one-month time frame. The move came after the company reported narrower-than-expected loss in fourth-quarter 2017.
Upvote Downvote

 
1
Pieris Pharmaceuticals' (PIRS) CEO Stephen Yoder on Q4 2017 Results - Earnings Call Transcript

2018-03-09 seekingalpha
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2017 Results Earnings Conference Call March 9, 2018 8:00 AM ET
Upvote Downvote

 
Pieris Pharmaceuticals Reports Full-Year 2017 Financial Results and Corporate Update

2018-03-09 marketwired
Company to Host an Investor Conference Call on Friday, March 9, 2018 at 8:00 Am Est
Upvote Downvote

 
 
Pieris Pharmaceuticals to Present at Investor Conferences in March

2018-03-06 marketwired
BOSTON, MA--(Marketwired - March 06, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Pieris will present at the following upcoming investor conferences:
Upvote Downvote

 
Pieris Pharmaceuticals to Host Full-Year 2017 Investor Call and Corporate Update on March 9, 2018

2018-02-28 marketwired
BOSTON, MA--(Marketwired - February 28, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it will host a full-year 2017 investor call on Friday, March 9, 2018 at 8:00 AM (EST) to discuss financial results and provide a corporate update.
Upvote Downvote

 
PIRS / Pieris Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-22 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2018   PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)    Nevada   001-37471   EIN 30-0784346 (State of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
PIRS / Pieris Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 (Activist Investment)

2018-02-21 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* PIERIS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 720795103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP III LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone:  (212) 739-6400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) (Name, Addre
Upvote Downvote

 
PIRS / Pieris Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 (Activist Investment)

2018-02-21 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* PIERIS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 720795103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP III LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone:  (212) 739-6400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) (Name, Addre
Upvote Downvote

 
PIRS / Pieris Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-20 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2018   PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)    Nevada   001-37471   EIN 30-0784346 (State of Incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

PIRS : Pieris Pharmaceuticals Stock Analysis and Research Report

2017-10-20 - Asif

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. Each of its development programs focus on the following: 300-Series oncology drug candidates are multispecific Anticalin®-based proteins designed to engage immunomodulatory targets and consist of a variety of multifunctional biotherapeutics that genetically link antibody with one or more Anticalin proteins, thereby constituting...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 720795103